Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Investigational New Drugs|February 19, 2014
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumorsRamón Salazar, Antonio Calles, Marta Gil, et al.
International Journal of Molecular Sciences|April 13, 2024
In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 TherapiesAdrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2018
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumoursAnas Gazzah, Valentina Boni, Jean-Charles Soria, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction StudyIrene Moreno, Tatiana Hernández, Emiliano Calvo, et al.
Cancer Metastasis Reviews|July 20, 2010
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populationsEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
Cancer Metastasis Reviews|July 20, 2010
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinomaEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
American Journal of Respiratory and Critical Care Medicine|March 3, 2010
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinomaDorothy A White, Philippe Camus, Masahiro Endo, et al.
Marine Drugs|April 26, 2024
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction StudyIrene Moreno, Tatiana Hernández, Emiliano Calvo, et al.
Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.
Investigational New Drugs|August 10, 2022
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumorsEmiliano Calvo, Cristiana Sessa, Guilherme Harada, et al.
Pageof 16